The European Commission has opened a formal antitrust investigation to determine whether Zoetis, one of the largest purveyors of medicines for dogs and cats, breached European Union competition rules by preventing the launch of a competing novel medicine that is used to treat chronic pain in canines.
The company sells the first and only monoclonal antibody, called Librela, that is available to treat pain stemming from osteoarthritis suffered by dogs. As the EC noted, the treatment, which is administered monthly, offers a novel option for relieving pain, especially in older dogs. Librela was approved by European regulators in 2020 and in the U.S., where Zoetis is headquartered, in 2023.
But at the same time that Zoetis was developing its drug, it acquired another late-stage treatment for the same use, and this was supposed to be sold in the European Economic Area by another company. The EC is concerned that Zoetis may have broken antitrust laws by ending development of that drug and refusing to transfer it to the other company, which had exclusive commercial rights in the EEA.
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.